Free Trial

Mathew Blackman Analyst Performance

Analyst at TD Cowen

Mathew Blackman is a stock analyst at TD Cowen in the medical sector, covering 13 publicly traded companies. Over the past year, Mathew Blackman has issued 12 stock ratings, including strong buy, buy, and hold recommendations. While full access to Mathew Blackman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mathew Blackman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
22 Last 7 Years
Buy Recommendations
81.82% 18 Buy Ratings
Companies Covered
13 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy13.6%3 ratings
Buy68.2%14 ratings
Hold18.2%4 ratings
Sell0.0%0 ratings

Out of 22 total stock ratings issued by Mathew Blackman at TD Cowen, the majority (68.2%) have been Buy recommendations, followed by 18.2% Hold and 13.6% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
84.6% of companies on NASDAQ
11 companies
NYSE
15.4% of companies on NYSE
2 companies

Mathew Blackman, an analyst at TD Cowen, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
13 companies
100.0%

Mathew Blackman of TD Cowen specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED INSTRUMENTS
10 companies
76.9%
MED PRODUCTS
3 companies
23.1%

Mathew Blackman's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4/20/2026Reiterated Rating$20.61$28.00Buy
SiBone stock logo
SIBN
SiBone
2/24/2026Boost Price Target$15.62$22.00Buy
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
1/27/2026Initiated Coverage$13.24$14.00Hold
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
1/27/2026Upgrade$525.04Strong-Buy
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
1/27/2026Upgrade$17.74Strong-Buy
SiBone stock logo
SIBN
SiBone
1/27/2026Upgrade$17.03Strong-Buy
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
1/26/2026Initiated Coverage$15.46$17.00Hold
SiBone stock logo
SIBN
SiBone
1/26/2026Initiated Coverage$17.14$21.00Buy
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
1/26/2026Initiated Coverage$17.78$23.00Buy
Intuitive Surgical, Inc. stock logo
ISRG
Intuitive Surgical
1/26/2026Initiated Coverage$528.81$660.00Buy
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
8/1/2025Boost Price Target$10.11$9.00Buy
Inogen, Inc stock logo
INGN
Inogen
5/8/2025Lower Price Target$5.99$7.00Hold
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
5/1/2025Lower Price Target$19.66$31.00Buy
Penumbra, Inc. stock logo
PEN
Penumbra
4/24/2025Set Price Target$277.24$318.00Buy
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
4/1/2025Boost Price Target$11.89$25.00Buy
Beta Bionics, Inc. stock logo
BBNX
Beta Bionics
2/24/2025Initiated Coverage$20.57$25.00Buy
Insulet Corporation stock logo
PODD
Insulet
2/21/2025Boost Price Target$282.42$293.00Hold
Globus Medical, Inc. stock logo
GMED
Globus Medical
2/21/2025Boost Price Target$82.11$94.00Buy
Cerus Corporation stock logo
CERS
Cerus
10/17/2024Lower Price Target$1.47$3.00Buy